Advances in the diagnosis and management of von Willebrand disease

Hematology

Volumn 11, Issue 4, 2006, Pages 219-225

  Franchini, Massimo ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Bleeding; Diagnosis; von Willebrand disease; von Willebrand factor

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; HEMATOLOGIC AGENT; PLASMA DERIVED BLOOD CLOTTING FACTOR 8 CONCENTRATE VON WILLEBRAND FACTOR CONCENTRAT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ANAMNESIS; ANAPHYLAXIS; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BLEEDING; BLOOD TRANSFUSION; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; FAMILY HISTORY; FLUSHING; HEMOSTASIS; HUMAN; HYPONATREMIA; LABORATORY TEST; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TACHYCARDIA; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

ANTIGENS; BIOPOLYMERS; CASE MANAGEMENT; DEAMINO ARGININE VASOPRESSIN; DISEASE MANAGEMENT; FACTOR VIII; GENES, DOMINANT; GENES, RECESSIVE; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HUMANS; PHENOTYPE; PLATELET COUNT; PROTEIN SUBUNITS; RETROSPECTIVE STUDIES; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 33845705369     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330600841311     Document Type: Review

References (50)

1. Castaman, G and Federici, AB and Rodeghiero, F and Mannucci, PM. (2003) von Willebrand's disease in the year 2003: Towards the complete identification of gene defects for correct diagnosis and treatment Haematologica, 88, pp. 94-108.
2. Rodeghiero, F and Castaman, G and Dini, E. (1987) Epidemiological investigation of the prevalence of von Willebrand's disease Blood, 69, pp. 454-459.
3. Federici, AB and Castaman, G and Mannucci, PM. (2002) Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy Haemophilia, 8, pp. 607-621.
4. Sadler, JE. (1994) A revised classification of von Willebrand disease Thromb Haemost, 71, pp. 520-525.
5. Federici, AB. (2004) Clinical diagnosis of von Willebrand disease Haemophilia, 10(Suppl. 4), pp. 169-176.
6. Miller, CH and Graham, JB and Goldin, LR and Elston, RC. (1979) Genetics of classic von Willebrand's disease. I. Phenotypic variation within families Blood, 54, pp. 117-136.
7. Weiss, HJ and Pietu, G and Rabinowitz, R and Girma, JP and Rogers, J and Meyer, D. (1983) Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor insubtypes of classic (type I) and variant (IIA) von Willebrand's disease J Lab Clin Med, 101, pp. 411-425.
8. Mannucci, PM and Lombardi, R and Bader, R and (1985) Heterogeneity of type I von Willebrand disease: Evidence for a subgroup with an abnormal von Willebrand factor Blood, 66, pp. 796-802.
9. Favaloro, EJ and Lillicrap, D and Lazzari, MA and (2004) von Willebrand disease: Laboratory aspects of diagnosis and treatment Haemophilia, 10(Suppl. 4), pp. 164-168.
10. Laffan, M and Brown, SA and Collins, PW and (2004) The diagnosis of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors' Organization Haemophilia, 10, pp. 199-217.
11. Weiss, HJ and Meyer, D and Rabinowitz, R and (1982) Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers N Engl J Med, 306, pp. 326-333.
12. Miller, JL and Castella, A. (1982) Platelet-type von Willebrand's disease: Characterization of a new bleeding disorder Blood, 60, pp. 790-794.
13. Nishino, M and Girma, JP and Rothschild, C and Fressinaud, E and Meyer, D. (1989) New variant of von Willebrand disease with defective binding to factor VIII Blood, 74, pp. 1591-1599.
14. Mazurier, C and Dieval, J and Jorieux, S and Delobel, J and Goudemand, M. (1990) A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction Blood, 75, pp. 20-26.
15. Fressinaud, E and Veyradier, A and Trichaud, F and (1998) Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases Blood, 91, pp. 1325-1331.
16. Franchini, M. (2005) The platelet function analyzer (PFA-100): An update on its clinical use Clin Lab, 51, pp. 367-372.
17. Federici, AB and Canciani, MT and Forza, I and Cozzi, G. (2000) Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease - single center comparison of four different assays Thromb Haemost, 84, pp. 1127-1128.
18. Federici, AB and de Groot, PG and Moia, M and Ijsseldijk, MJ and Sixma, JJ and Mannucci, PM. (1993) Type I von Willebrand disease, subtype "platelet low": Decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells Br J Haematol, 83, pp. 88-93.
19. Meyer, D and Fressinaud, E and Gaucher, C and Lavergne, JM and Hilbert, L and Ribba, AS and Jorieux, S and Mazurier, C. (1997) Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: From the patient to the gene. INSERM network on molecular abnormalities in von Willebrand disease Thromb Haemost, 78, pp. 451-456.
20. Lyons, SE and Bruck, ME and Bowie, EJ and Ginsburg, D. (1992) Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations J Biol Chem, 267, pp. 4424-4430.
21. Schneppenheim, R and Budde, U and Ruggeri, ZM. (2001) A molecular approach to the classification of von Willebrand disease Best Pract Res Clin Haematol, 14, pp. 281-298.
22. Sadler, JE. (2005) New concepts in von Willebrand disease Annu Rev Med, 56, pp. 173-1791.
23. Ruggeri, ZM. (2004) Type IIB von Willebrand disease: A paradox explains how von Willebrand factor works J Thromb Haemost, 2, pp. 2-6.
24. Savage, B and Saldivar, E and Ruggeri, ZM. (1996) Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor Cell, 84, pp. 289-297.
25. Miura, S and Li, CQ and Cao, Z and Wang, H and Wardell, MR and Sadler, JE. (2000) Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion J Biol Chem, 275, pp. 7539-7546.
26. Mancuso, DJ and Kroner, PA and Christopherson, PA and Vokac, EA and Gill, JC and Montgomery, RR. (1996) Type 2M: Milwaukee-1 von Willebrand disease: An in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets Blood, 88, pp. 2259-2568.
27. Hillery, CA and Mancuso, DJ and Sadler, JE and (1998) Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets Blood, 91, pp. 1572-1581.
28. Mannucci, PM and Lombardi, R and Castaman, G and (1988) von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers Blood, 71, pp. 65-70.
29. Schneppenheim, R and Federici, AB and Budde, U and (2000) Von Willebrand disease type 2M "Vicenza" in Italian and German patients: Identification of the first candidate mutation (G3864A; R1205H) in 8 families Thromb Haemost, 82, pp. 136-140.
30. Mazurier, C and Goudemand, J and Hilbert, L and Caron, C and Fressinaud, E and Meyer, D. (2001) Type 2N von Willebrand disease: Clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology Best Pract Res Clin Haematol, 14, pp. 337-347.
31. Sadler, JE and Mannucci, PM and Berntorp, E and Bochkov, N and Boulyjenkov, V and Ginsburg, D and Meyer, D and Peake, I and Rodeghiero, F and Srivastava, A. (2000) Impact, diagnosis and treatment of von Willebrand disease Thromb Haemost, 84, pp. 160-174.
32. Mannucci, PM and Ruggeri, ZM and Ciavarella, N and Kazatchkine, MD and Mowbray, JF. (1981) Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: Effects on replacement therapy Blood, 57, pp. 25-31.
33. Pasi, KJ and Collins, PW and Keeling, DM and (2004) Management of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors' Organization Haemophilia, 10, pp. 218-231.
34. Mannucci, PM. (2004) Treatment of von Willebrand's disease N Engl J Med, 351, pp. 683-694.
35. Mannucci, PM. (1998) Hemostatic drugs N Engl J Med, 339, pp. 245-253.
36. Nitu-Whalley, IC and Griffioen, A and Harrington, C and Lee, CA. (2001) Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease Am J Hematol, 66, pp. 280-284.
37. Federici, AB and Mazurier, C and Berntorp, E and (2004) Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study Blood, 103, pp. 2032-2038.
38. Mannucci, PM and Federici, AB. (2001) Management of inherited von Willebrand disease Best Pract Res Clin Haematol, 14, pp. 455-462.
39. Rodeghiero, F and Castaman, G and Mannucci, PM. (1991) Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease Blood Rev, 5, pp. 155-161.
40. Smith, TJ and Gill, JC and Ambruso, DR and Hathaway, WE. (1989) Hyponatremia and seizures in young children given DDAVP Am J Hematol, 31, pp. 199-202.
41. Mannucci, PM and Lusher, JM. (1989) Desmopressin and thrombosis Lancet, 2, pp. 675.
42. Mannucci, PM. (2001) How I treat patients with von Willebrand disease Blood, 97, pp. 1915-1919.
43. Mannucci, PM. (2000) Desmopressin (DDAVP) in the treatment of bleeding disorders: The first twenty years Haemophilia, 6(Suppl. 1), pp. 60-67.
44. Mannucci, PM and Chediak, J and Hanna, W and Byrnes, J and Marlies, L and Ewenstein, BM. (2002) Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study Blood, 99, pp. 450-456. and the Alphanate Study Group
45. Franchini, M and Rossetti, G and Tagliaferri, A and Pattacini, C and Pozzoli, D and Lippi, G and Manzato, F and Bertuzzo, D and Gandini, G. (2003) Efficacy and safety of factor VIII/von Willebrand factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand's disease Haematologica, 88, pp. 1279-1283.
46. Rosendaal, FR. (2000) High levels of factor VIII and venous thrombosis Throm Haemost, 83, pp. 1-2.
47. Mannucci, PM. (2002) Venous thromboembolism in von Willebrand disease Thromb Haemost, 88, pp. 378-379.
48. Makris, M and Colvin, B and Gupta, V and Shields, ML and Smith, MP. (2002) Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease Thromb Haemost, 88, pp. 387-388.
49. Rodeghiero, F and Castaman, G. (2005) Treatment of von Willebrand disease Semin Hematol, 42, pp. 29-35.
50. Mannucci, PM and Tamaro, G and Narchi, G and Candotti, G and Federici, A and Altieri, D and Tedesco, F. (1987) Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor Eur J Haematol, 39, pp. 467-470.